ArticleTrials2022

Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial.

Etienne Karita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.